CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 5 enrolled
Drug / intervention
Tiotropiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00870896
NCT00870896Early Ph 1Completed
CompareCT.gov

The Effects of Tiotropium on the Cough Reflex in Patients With COPD

ThomasTruncale·interventional·Posted Mar 27, 2009·Updated Oct 1, 2014

In Brief

A Early Phase 1 clinical trial evaluating Tiotropium for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis. Completed, enrolled 5 participants across 2 sites.

Detailed Summary

Does tiotropium effect the cough reflex in patients with COPD and chronic bronchitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease, Chronic Bronchitis
CountriesUnited States
CollaboratorsBoehringer Ingelheim

Timeline

Early Ph 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 27, 2009
Enrollment StartFeb 1, 2008
Primary CompletionFeb 1, 2009
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.3 years ago

Interventions

Tiotropiumdrug

Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.